维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

9篇 您的检索式：作者名="SUNEEL D"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Enzymatic polishing of rice-a new processing technology显示文摘	Mithu D Suneel G Vishal K	2008	Food Science and Technology2008，41，10：	1
	2	Mucoadhesive buccal tablets of domperidone:formulationevaluation and effects of process variables 显示文摘	Suneel L P Nilesh T H Ujjalkumar D	2014	J Pharm Investig2014，44，2：	1
	3	Defining the dynamics of self-assembled Fas-receptor activation显示文摘	Suneel D Mundle Azra Raza	2002	Trends in Immunology2002，23，4：	1
	4	Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1显示文摘	YIFWAYIMARE M JONATHAN D C	2000	Br J Haematol2000，109，2：	1
	5	Enzymatic polishing of rice: a new processing technology显示文摘	M1THU D SUNEEL G VISHAL K	2008	LWT - Food Science and Technology2008，41，10：	1
	6	Enzymatic polishing of rice: a new processing technology显示文摘	MITHU D SUNEEL G VISHAL K	2008	LWT - Food Science and Technology2008，41，10：	1
	7	Defining the dynamics of self-assembled Fas-receptor activation 显示文摘	SUNEEL D MUNDLE AZRA RAZA	2002	Trends in Immunology2002，23，4：	1
	8	Defining the dynamics of self-assembled Fas-receptor activation显示文摘	Suneel D Mundle Azra Raza	2002	Trends in Immunology2002，23，4：	1
	9	Apalutamide for metastatic castration-sensitive prostate cancer:final analysis of the Asian subpopulation in the TITAN trial显示文摘The final analysis of the phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen(TITAN)trial showed improvement in overall survival(OS)and other efficacy endpoints with apalutamide plus androgen deprivation therapy(ADT)versus ADT alone in patients with metastatic castration-sensitive prostate cancer(mCSPC).As ethnicity and regional differences may affect treatment outcomes in advanced prostate cancer,a post hoc final analysis was conducted to assess the efficacy and safety of apalutamide in the Asian subpopulation.Event-driven endpoints were OS,and time from randomization to initiation of castration resistance,prostate-specific antigen(PSA)progression,and second progression-free survival(PFS2)on first subsequent therapy or death.Efficacy endpoints were assessed using the Kaplan–Meier method and Cox proportional-hazards models without formal statistical testing and adjustment for multiplicity.Participating Asian patients received once-daily apalutamide 240 mg(n=111)or placebo(n=110)plus ADT.After a median follow-up of 42.5 months and despite crossover of 47 placebo recipients to open-label apalutamide,apalutamide reduced the risk of death by 32%(hazard ratio[HR]:0.68;95%confidence interval[CI]:0.42–1.13),risk of castration resistance by 69%(HR:0.31;95%CI:0.21–0.46),PSA progression by 79%(HR:0.21;95%CI:0.13–0.35)and PFS2 by 24%(HR:0.76;95%CI:0.44–1.29)relative to placebo.The outcomes were comparable between subgroups with low-and high-volume disease at baseline.No new safety issues were identified.Apalutamide provides valuable clinical benefits to Asian patients with mCSPC,with an efficacy and safety profile consistent with that in the overall patient population.	Byung Ha Chung Jian Huang Hiroji Uemura Young Deuk Choi Zhang-Qun Ye Hiroyoshi Suzuki Taek Won Kang Da-Lin He Jae Young Joung Sabine D Brookman-May Sharon McCarthy Amitabha Bhaumik Anildeep Singh Suneel Mundle Simon Chowdhury Neeraj Agarwal Ding-Wei Ye Kim N Chi Hirotsugu Uemura	2023	Asian Journal of Andrology2023，25，6：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费